A 5-year follow-up of antibody response in children vaccinated with single dose of live attenuated SA14-14-2 Japanese encephalitis vaccine: Immunogenicity and anamnestic responses-Reference-Cited by-同舟云学术

A 5-year follow-up of antibody response in children vaccinated with single dose of live attenuated SA14-14-2 Japanese encephalitis vaccine: Immunogenicity and anamnestic responses

Published:2008-03 Issue:13 Volume:26 Page:1638-1643
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Sohn Young Mo,Tandan J.B.,Yoksan Sutee,Ji Min,Ohrr Heechoul

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference16 articles.

1. Epidemiology and control of Japanese encephalitis;Igarashi;World Health Stat Q,1992

2. Japanese encephalitis: current worldwide status;Umenai;Bull World Health Organ,1985

3. Japanese encephalitis;Solomon;J Neurol Neurosurg Psychiatry,2000

4. New initiatives for the control of Japanese encephalitis by vaccination;Tsai;Vaccine,2000

5. Effectiveness of live-attenuated Japanese encephalitis vaccine (SA14-14-2): a case-control study;Hennessy;Lancet,1996

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of vaccination against Japanese encephalitis in endemic countries;PLOS Neglected Tropical Diseases;2024-09-03

2. Antibodies from dengue patients with prior exposure to Japanese encephalitis virus are broadly neutralizing against Zika virus;Communications Biology;2024-01-24

3. Japanese Encephalitis Vaccines;Plotkin's Vaccines;2023

4. Persistence of antibodies, boostability, and interchangeability of Japanese encephalitis vaccines: A systematic review and dose-response meta-analysis;Vaccine;2022-06

5. Antibody persistence and immune memory response following primary vaccination and boosting with live attenuated SA 14-14-2 Japanese encephalitis vaccine (CD-JEV) in Bangladesh: A phase 4 open-label clinical trial;Vaccine: X;2022-04